The New England Journal of Medicine has published correspondence reporting pregnancies in patients with autoimmune disease who had previously received CAR T-cell therapy, a relatively new treatment that reprogrammes the body’s immune cells.
The journal posted the findings on X, flagging the correspondence under the hashtags #OBGYN and #Immunology. CAR T-cell therapy — short for chimeric antigen receptor T-cell therapy — involves taking a patient’s own white blood cells, modifying them in a laboratory, and returning them to the body to target problem cells in the immune system. It has been used in cancer treatment for some years, and its use in autoimmune conditions is more recent.
The correspondence addresses what happens to patients who become pregnant after receiving this treatment — a question with clear consequences for women of childbearing age who are being considered for, or have already undergone, the therapy.
No specific figures, patient outcomes or clinical conclusions are quoted in the post itself. The full details sit within the journal correspondence.
Anyone with questions about autoimmune conditions, fertility, or treatment options should speak to their GP in the first instance, or call NHS 111 for guidance.
Source: @NEJM
Pregnancies Reported in Autoimmune Patients Who Received CAR T-Cell Therapy, New England Journal of Medicine Says Quiz
5 questions